RLMD RSI Chart
Last 7 days
-17.5%
Last 30 days
-21.2%
Last 90 days
6.6%
Trailing 12 Months
53.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 | 6.2M |
2020 | 0 | 0 | 818.3K | 0 |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 0 |
2017 | 0 | 96.4K | 0 | 0 |
2014 | 66.0K | 0 | 0 | 0 |
2013 | 6.5K | 5.8K | 5.1K | 35.6K |
2012 | 0 | 0 | 7.9K | 7.2K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 31, 2024 | ence chuck | bought | 55,429 | 4.0548 | 13,670 | ca and co |
Jan 31, 2024 | shenouda maged | bought | 27,943 | 4.0645 | 6,875 | chief financial officer |
Jan 31, 2024 | traversa sergio | bought | 109,752 | 3.9968 | 27,460 | chief executive officer |
Jan 30, 2024 | shenouda maged | bought | 58,323 | 3.8882 | 15,000 | chief financial officer |
Jan 30, 2024 | traversa sergio | bought | 159,949 | 3.9013 | 40,999 | chief executive officer |
Jan 30, 2024 | ence chuck | bought | 56,052 | 3.8657 | 14,500 | ca and co |
Jan 29, 2024 | ence chuck | bought | 39,438 | 3.6517 | 10,800 | ca and co |
Jan 29, 2024 | shenouda maged | bought | 39,450 | 3.6528 | 10,800 | chief financial officer |
Jan 29, 2024 | traversa sergio | bought | 117,036 | 3.7106 | 31,541 | chief executive officer |
May 23, 2023 | o'gorman cedric | bought | 31,800 | 3.18 | 10,000 | chief medical officer |
Which funds bought or sold RLMD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 22, 2024 | PARSONS CAPITAL MANAGEMENT INC/RI | added | 2.49 | 594,526 | 4,526,870 | 0.31% |
Apr 19, 2024 | Cutler Group LLC / CA | reduced | -3.23 | 3,000 | 41,000 | 0.01% |
Apr 18, 2024 | Hexagon Capital Partners LLC | unchanged | - | 2,040 | 18,600 | -% |
Apr 16, 2024 | Stratos Wealth Partners, LTD. | reduced | -14.55 | -2,745 | 65,565 | -% |
Apr 11, 2024 | Fortitude Family Office, LLC | unchanged | - | 173 | 1,581 | -% |
Apr 11, 2024 | MEYER HANDELMAN CO | unchanged | - | 16,598 | 151,334 | -% |
Apr 09, 2024 | MASSMUTUAL TRUST CO FSB/ADV | unchanged | - | 57.00 | 525 | -% |
Apr 09, 2024 | American Capital Advisory, LLC | new | - | 4,968 | 4,968 | -% |
Apr 05, 2024 | GAMMA Investing LLC | unchanged | - | 410 | 2,646 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.06 | 1,496,630 | 5,426,730 | -% |
Unveiling Relmada Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Relmada Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.6B | 6.8B | -8.82 | 6.07 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.14 | 9.91 | ||||
BMRN | 17.2B | 2.4B | 102.64 | 7.11 | ||||
INCY | 11.6B | 3.7B | 19.44 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.39 | 15.18 | ||||
BBIO | 4.4B | - | -6.74 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.09 | 12.46 | ||||
ARWR | 2.9B | 240.7M | -9.72 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -44.6 | 3.76 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.96 | 4.48 | ||||
NVAX | 580.8M | 983.7M | -1.07 | 0.59 | ||||
CRBP | 372.9M | 881.7K | -8.36 | 466.16 | ||||
INO | 237.4M | 4.9M | -1.76 | 48.79 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Relmada Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2020Q3 | 2020Q2 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 |
Revenue | - | - | - | - | - | 5,361,518 | 363,300 | 404,004 | 37,916 | 13,110 | - | - | - | - | - | - | - | - | - | - | - | 634 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.00 | 164 | - | 312 |
Operating Expenses | 18.2% | 26,829,320 | 22,692,638 | 26,026,726 | 28,153,609 | 38,702,420 | 17,183,582 | 12,757,202 | 3,707,410 | 4,135,702 | 2,702,004 | 3,478,984 | 2,411,230 | 1,930,123 | 2,549,911 | - | - | - | - | - | - | - |
S&GA Expenses | -1.3% | 12,077,259 | 12,238,566 | 12,286,521 | 12,292,599 | 11,834,053 | 5,946,396 | 7,433,249 | 1,820,043 | 1,065,803 | 1,426,056 | 2,221,566 | 989,748 | 970,870 | 883,009 | - | - | - | - | - | - | - |
R&D Expenses | 41.1% | 14,752,061 | 10,454,072 | 13,740,205 | 15,861,010 | 26,868,367 | 11,237,186 | 5,323,953 | 1,887,367 | 3,069,899 | 1,275,948 | 1,257,418 | 1,421,482 | 959,253 | 1,666,902 | - | - | - | - | - | - | - |
Interest Expenses | -4.7% | 1,259,226 | 1,321,441 | 1,363,406 | 1,207,631 | 1,114,527 | 363,300 | 404,004 | 37,916 | 13,110 | 15,939 | -139,765 | -650,322 | -630,366 | -397,111 | - | - | - | - | - | - | - |
Net Income | -14.4% | -25,165,158 | -22,002,058 | -25,302,954 | -26,321,576 | -37,944,365 | -16,902,507 | -11,118,441 | -3,669,494 | -4,122,592 | -2,686,065 | -7,129,310 | -3,380,093 | -3,349,932 | -3,201,884 | - | - | - | - | - | - | - |
Net Income Margin | -1825.0% | -120 | 7.00 | -14.28 | -32.16 | -48.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 11.9% | -10,249,714 | -11,631,129 | -13,273,269 | -16,505,094 | -35,882,900 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -10.6% | 98.00 | 109 | 122 | 136 | 153 | 187 | 216 | 226 | 223 | 91.00 | 111 | 104 | 118 | 126 | 135 | 115 | 117 | 9.00 | 10.00 | 3.00 | 3.00 |
Current Assets | -10.6% | 98.00 | 109 | 122 | 136 | 153 | 187 | 216 | 226 | 223 | 91.00 | 111 | 104 | 118 | 125 | 134 | 115 | 117 | 8.00 | 10.00 | 2.00 | 3.00 |
Cash Equivalents | -38.9% | 4.00 | 7.00 | 14.00 | 29.00 | 5.00 | 43.00 | 37.00 | 45.00 | 44.00 | 11.00 | 5.00 | 4.00 | 2.00 | 8.00 | 14.00 | 12.00 | 36.00 | 8.00 | 9.00 | 2.00 | 2.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | 452* | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | - | 12.00 | - | - | 10.00 | 12.00 | - | - | 15.00 | 15.00 | 14.00 | 14.00 | 13.00 | 13.00 | - | - | - | 1.00 | 3.00 | 3.00 | 2.00 | 2.00 |
Current Liabilities | 44.8% | 12.00 | 8.00 | 11.00 | 10.00 | 12.00 | 21.00 | 19.00 | 15.00 | 15.00 | 18.00 | 14.00 | 13.00 | 13.00 | 3.00 | 2.00 | 2.00 | 1.00 | - | 3.00 | 2.00 | 2.00 |
Shareholder's Equity | -15.3% | 85.00 | 101 | 111 | 125 | 140 | 166 | 197 | 210 | 208 | 73.00 | 97.00 | 91.00 | 106 | 122 | 132 | 113 | 116 | 6.00 | 8.00 | 0.00 | 1.00 |
Retained Earnings | -4.7% | -560 | -535 | -513 | -488 | -462 | -424 | -384 | -344 | -305 | -270 | -228 | -201 | -179 | -158 | -141 | -130 | -119 | -115 | -111 | -107 | -104 |
Additional Paid-In Capital | 1.5% | 646 | 636 | 625 | 614 | 603 | 590 | 582 | 555 | 513 | 343 | 325 | 293 | 285 | 281 | 274 | 244 | 236 | 121 | 119 | 108 | 106 |
Shares Outstanding | 0% | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 29.00 | 29.00 | 28.00 | 17.00 | 17.00 | 17.00 | 16.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | 73.00 | - | - | - | 563 | - | - | - | 547 | - | - | - | 695 | - | - | - | 70.00 | - | 9.00 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 11.9% | -10,249 | -11,631 | -13,273 | -16,505 | -35,882 | -26,862 | -21,626 | -19,429 | -37,660 | -20,916 | -17,211 | -16,085 | -6,928 | -12,501 | -4,953 | -3,424 | -3,879 | -2,534 | -3,667 | -2,011 | -3,147 |
Share Based Compensation | -13.2% | 9,894 | 11,393 | 11,170 | 11,354 | 11,626 | 8,343 | 12,295 | 11,931 | 18,361 | 8,014 | 8,268 | 5,851 | 3,191 | 5,245 | 7,303 | 5,039 | 1,609 | 758 | 403 | 395 | 263 |
Cashflow From Investing | 100.5% | 7,741 | 3,860 | -1,151 | 40,004 | -1,655 | 31,557 | -140 | -10,027 | -91,182 | 27,511 | -5,912 | 15,466 | 935 | 4,588 | -16,338 | -23,632 | - | - | - | - | - |
Cashflow From Financing | - | - | - | - | - | 410 | 569 | 14,093 | 29,948 | 161,837 | 185 | 23,989 | 1,928 | 944 | 1,634 | 22,890 | 3,005 | 112,473 | 1,167 | 10,830 | 1,639 | 4,687 |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 54,807,348 | $ 113,322,999 |
General and administrative | 48,894,945 | 47,926,077 |
Total operating expenses | 103,702,293 | 161,249,076 |
Loss from operations | (103,702,293) | (161,249,076) |
Other income (expenses): | ||
Gain on settlement of fees | 6,351,606 | |
Interest/investment income, net | 5,151,704 | 2,659,424 |
Realized loss on short-term investments | (4,064,391) | (585,522) |
Unrealized gain (loss) on short-term investments | 3,823,234 | (4,220,255) |
Total other income (expenses), net | 4,910,547 | 4,205,253 |
Net loss | $ (98,791,746) | $ (157,043,823) |
Net loss per common share – basic and diluted (in Dollars per share) | $ (3.28) | $ (5.3) |
Weighted average number of common shares outstanding – basic and diluted (in Shares) | 30,099,203 | 29,628,664 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,091,568 | $ 5,395,905 |
Short-term investments | 92,232,292 | 142,926,781 |
Other receivables | 512,432 | |
Prepaid expenses | 1,185,057 | 4,035,186 |
Total current assets | 97,508,917 | 152,870,304 |
Other assets | 43,125 | 34,875 |
Total assets | 97,552,042 | 152,905,179 |
Current liabilities: | ||
Accounts payable | 3,506,009 | 5,261,936 |
Accrued expenses | 8,688,791 | 7,206,941 |
Total current liabilities | 12,194,800 | 12,468,877 |
Total liabilities | 12,194,800 | 12,468,877 |
Commitments and Contingencies | ||
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding | ||
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding | ||
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,099,203 and 30,099,203 shares issued and outstanding, respectively | 30,099 | 30,099 |
Additional paid-in capital | 646,229,824 | 602,517,138 |
Accumulated deficit | (560,902,681) | (462,110,935) |
Total stockholders’ equity | 85,357,242 | 140,436,302 |
Total liabilities and stockholders’ equity | $ 97,552,042 | $ 152,905,179 |